CLINICAL_TRIALS
ClinicalTrials.gov record update
Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04370834
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:53.986900+00:00
- Published At
- 2021-06-04T00:00:00+00:00
- Record Updated At
- 2025-02-04
- Results Posted At
- 2021-06-04
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Pneumonia", "Pneumonitis", "Severe Acute Respiratory Distress Syndrome", "Symptomatic COVID-19 Infection Laboratory-Confirmed"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-02-04"- protocolSection.identificationModule.nctId
"NCT04370834"- protocolSection.identificationModule.officialTitle
"Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-06-04"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.